Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Symptomatic dermographism: a systematic review of treatment options
Filename | 403. Kulthanan et al., Symptomatic Dermograph., JACIinPract2020.pdf |
Filesize | 473.61 KB |
Version | o.403 |
Date added | November 13, 2020 |
Downloaded | 4 times |
Category | Original Work |
Tags | Symptomatic dermographism, systematic review, treatment |
Authors | Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Rujitharanawong, C., Kiratiwongwan, R., Jantanapornchai, N., Hawro, T., and Maurer, M. |
Citation | Kulthanan, K., Ungprasert, P., Tuchinda, P., Chularojanamontri, L., Rujitharanawong, C., Kiratiwongwan, R., Jantanapornchai, N., Hawro, T., and Maurer, M.: Symptomatic dermographism: a systematic review of treatment options. J. Allergy Clin. Immunol. Pract. 2020: 8; 3141-3161. |
Corresponding authors | Maurer, M. |
DocNum | o.403 |
DocType | |
IF | 8.86 |
Publisher | J. Allergy Clin. Immunol. Pract. |
ReleaseDate | 2020 |
BACKGROUND: Symptomatic dermographism (SD), the most common form of chronic inducible urticaria, presents with transient wheals accompanied by itching in response to scratching. Little is known about available treatment options and their efficacy in SD.
OBJECTIVE: To systematically review the efficacy of treatment options for patients with SD.
METHODS: Using predefined search terms, we searched for relevant literature published until September 2019. The systematic review process was consistent with Preferred Reporting Items for Systematic Reviews and Meta-Analysis recommendations. RESULTS: The 23 studies identified included 15 randomized controlled trials; 22 and 17 assessed treatment responses in patients with SD by provocation/threshold testing and patient/physician clinical assessment, respectively. Thirteen different treatments were investigated in a total of 430 adult patients. The most frequently studied therapy, first-generation H1-antihistamines, showed variable efficacy and significant side effects. In contrast, second-generation H1-antihistamines (2ndAH1), in all studies, were effective and well tolerated. Monotherapy with an H2-antihistamine (AH2) was not effective, whereas adding an AH2 increased the efficacy of treatment with an H1-antihistamine (AH1). SD improved with omalizumab. All other treatments were only investigated in small, unrepeated, and/or uncontrolled studies. There are no studies on updosing of 2ndAH1.
CONCLUSIONS: The available SD studies are heterogeneous, mostly monocentric, old, small, and unrepeated, pointing to a high need for more and better studies. We suggest that 2ndAH1 should be the first-line treatment. In uncontrolled cases, the combination of AH1 and AH2 may be tried. Even though there is no evidence of its efficacy over standard dosage, updosing of 2ndAH1 may be considered based on the extrapolation of evidence from chronic spontaneous urticaria; omalizumab should be added in recalcitrant patients. 2020 American Academy of Allergy, Asthma & Immunology ( J Allergy Clin Immunol Pract 2020;8:3141-61)
(Last update: 12.2023)
Number of original publications in peer-reviewed journals: | 580 |
Number of reviews in peer-reviewed journals: | 210 |
Number of publications (original work and reviews) in peer-reviewed journals: | 790 |
Cumulative IF for original publications in peer-reviewed journals: | 4196.39 |
Cumulative IF for reviews in peer-reviewed journals: | 1409.32 |
Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 5605.71 |
Total number of citations: 36,836, h-index: 99 (Web of Science December 2023) | 36836 |
Download-Information
To be able to download the offered contents, you have to login. If you do not know the login, please write me your request.